The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Long-term evaluation of vascular toxicity in patients with Ph+ leukemias treated with bosutinib.
Jorge E. Cortes
Consultant or Advisory Role - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer; Teva
Research Funding - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer; Teva
Hagop M. Kantarjian
Research Funding - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer
Hanna Jean Khoury
Consultant or Advisory Role - Pfizer
Tim H. Brümmendorf
Consultant or Advisory Role - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer
Honoraria - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer
Research Funding - Novartis
Maureen G. Conlan
Employment or Leadership Position - Pfizer
Kongming Wang
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Kolette D. Fly
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer (B)
Mark Shapiro
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Jeffrey Howard Lipton
Consultant or Advisory Role - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer; Teva
Stock Ownership - ARIAD
Honoraria - Bristol-Myers Squibb; Novartis
Research Funding - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer; Teva
Jean-Bernard Durand
No relevant relationships to disclose
Carlo Gambacorti-Passerini
Consultant or Advisory Role - Bristol-Myers Squibb; Novartis; Pfizer
Research Funding - Pfizer